Basal cell carcinoma is the most common skin cancer, often caused by UV exposure, and originates in the epidermis's basal cells. Diagnosis involves clinical examination and biopsy to confirm BCC and ...

Skin cancer is the most common type of cancer in the United States with 5.4 million new cases of the disease reported every year. TODAY contributor and New Beauty editor-at-large Sarah Eggenberger ...

Reston, VA (August 21, 2025)--A topical fluorescent molecular contrast agent, PARPi-FL, can detect basal cell carcinoma through intact skin in as little as five minutes in ex vivo human tissues, ...

Comparison of the tolerability and safety of hedgehog inhibitors in real-life: A cohort of 330 patients with locally advanced basal cell carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Let’s face it — your pimple may be more problematic than you realize. A Harvard-trained dermatologist warns that some benign-seeming blemishes could be cancerous. Dr. Daniel Sugai urges patients with ...

Researchers from the Agency for Science, Technology and Research (A*STAR) and the National Healthcare Group (NHG) have jointly pioneered an innovative imaging technique combining Multispectral ...

Christie Brinkley is using a recent health scare to shine a light on the importance of skincare. In an Instagram post Wednesday, the model revealed she was diagnosed with early-stage skin cancer and ...

Basal cell carcinomas, the most common form of skin cancer, occur in chronically sun-exposed areas such as the face. Locally advanced tumors in particular can be difficult to treat surgically. A ...

Acinic cell carcinoma is a rare type of salivary gland cancer. It’s often treatable with surgery, but some people develop high-grade cancer that can spread to distant body parts. Acinic cell carcinoma ...

Gov. Kathy Hochul's recent announcement that she will have a basal cell carcinoma, a common form of skin cancer, removed this week may have many wondering what causes skin cancer and about the most ...

Belzutifan, a hypoxia-inducible factor 2α inhibitor, showed clinical activity in clear-cell renal-cell carcinoma in early-phase studies. In a phase 3, multicenter, open-label, active-controlled trial, ...